Nu-Med Plus (NUMD) Net Cash Flow Growth (3y) (2015 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -32.51% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | -87.87% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 42.74% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -11.49% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -87.88% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -48.90% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 129.29% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -65.12% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 33.47% |
| 10 | Nu-Med Plus | - | - | - | 62.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 62.51% |
| Sep 30, 2025 | -172.24% |
| Dec 31, 2024 | 56.43% |
| Jun 30, 2024 | 67.34% |
| Mar 31, 2024 | 79.09% |
| Dec 31, 2023 | -26.56% |
| Sep 30, 2023 | -39.98% |
| Jun 30, 2023 | -23.59% |
| Mar 31, 2023 | -55.95% |
| Dec 31, 2022 | 11.09% |
| Sep 30, 2022 | -71.15% |
| Jun 30, 2022 | 30.60% |
| Mar 31, 2022 | 60.14% |
| Dec 31, 2021 | -199.71% |
| Sep 30, 2021 | 30.12% |
| Jun 30, 2021 | -92.37% |
| Mar 31, 2021 | 13.33% |
| Dec 31, 2020 | 67.44% |
| Sep 30, 2020 | -44.15% |
| Jun 30, 2020 | 39.06% |
| Mar 31, 2020 | -66.72% |
| Dec 31, 2019 | -72.59% |
| Sep 30, 2019 | 39.55% |
| Jun 30, 2019 | 46.59% |
| Mar 31, 2019 | -65.61% |
| Dec 31, 2018 | -26.50% |
| Sep 30, 2018 | -125.36% |
| Jun 30, 2018 | 97.55% |
| Mar 31, 2018 | -20.44% |
| Dec 31, 2017 | -15.50% |
| Sep 30, 2017 | 38.63% |
| Jun 30, 2017 | -54.78% |
| Mar 31, 2017 | 286.39% |
| Dec 31, 2016 | -44.66% |
| Sep 30, 2016 | -646.61% |
| Jun 30, 2016 | -135.03% |
| Mar 31, 2016 | 166.87% |
| Dec 31, 2015 | 32.51% |
| Sep 30, 2015 | 14.44% |
| Jun 30, 2015 | 62.17% |
| Mar 31, 2015 | -40.03% |